Rheumatoid Arthritis Drug
Rheumatoid Arthritis Drug

Rheumatoid Arthritis Drug Comprehensive Study by Route of Administration (Oral, Parenteral), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Drug Class (Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Others) Players and Region - Global Market Outlook to 2026

Rheumatoid Arthritis Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 241 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Rheumatoid Arthritis Drug Market?

It is estimated that about 1.5 million Americans have rheumatoid arthritis. Rheumatoid Arthritis is a chronic inflammatory disorder that affects the joints, connective tissues, muscle, tendons, and fibrous tissue. It is the second most common type of arthritis. Rheumatoid arthritis drug's goal is to block inflammation that prevents joint damage. It has signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, joint stiffness, fatigue, fever and loss of appetite. NSAIDs are the most commonly used rheumatoid arthritis drugs.

The market study is being classified and major geographies with country level break-up.

Amgen Inc. (United States), UCB S.A. (Belgium), Eli Lilly and Company (United States), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (United States), Boehringer Ingelheim (Germany), Novartis International AG (Switzerland), Regeneron Pharmaceuticals, Inc. (United States), Pfizer (United States), Bristol-Myers Squibb Company (United States) and Johnson & Johnson (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Rheumatoid Arthritis Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Rheumatoid Arthritis Drug market by Type, Application and Region.

On the basis of geography, the market of Rheumatoid Arthritis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Global Prevalence of Rheumatoid Arthritis
  • Increased Number of Hospitals and Clinics

Market Trend
  • High Demand for Advanced Medical Treatment for Rheumatoid Arthritis
  • Increasing Awareness Regarding Rheumatoid Arthritis Disease

Restraints
  • Side Effects of the Drugs

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Robust Increase in the Distribution Channels

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Rheumatoid Arthritis Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Route of Administration
  • Oral
  • Parenteral

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Drug Class
  • Disease-modifying Anti-rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Global Prevalence of Rheumatoid Arthritis
      • 3.2.2. Increased Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Advanced Medical Treatment for Rheumatoid Arthritis
      • 3.4.2. Increasing Awareness Regarding Rheumatoid Arthritis Disease
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rheumatoid Arthritis Drug, by Route of Administration, End-users, Distribution Channel, Drug Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Rheumatoid Arthritis Drug (Value)
      • 5.2.1. Global Rheumatoid Arthritis Drug by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Parenteral
      • 5.2.2. Global Rheumatoid Arthritis Drug by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Rheumatoid Arthritis Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Rheumatoid Arthritis Drug by: Drug Class (Value)
        • 5.2.4.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • 5.2.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.2.4.3. Corticosteroids
        • 5.2.4.4. Uric Acid Drugs
        • 5.2.4.5. Others
      • 5.2.5. Global Rheumatoid Arthritis Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Rheumatoid Arthritis Drug (Volume)
      • 5.3.1. Global Rheumatoid Arthritis Drug by: Route of Administration (Volume)
        • 5.3.1.1. Oral
        • 5.3.1.2. Parenteral
      • 5.3.2. Global Rheumatoid Arthritis Drug by: End-users (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Ambulatory Surgical Centres
        • 5.3.2.4. Others
      • 5.3.3. Global Rheumatoid Arthritis Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
        • 5.3.3.4. Others
      • 5.3.4. Global Rheumatoid Arthritis Drug by: Drug Class (Volume)
        • 5.3.4.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • 5.3.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.3.4.3. Corticosteroids
        • 5.3.4.4. Uric Acid Drugs
        • 5.3.4.5. Others
      • 5.3.5. Global Rheumatoid Arthritis Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Rheumatoid Arthritis Drug (Price)
  • 6. Rheumatoid Arthritis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. UCB S.A. (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Rheumatoid Arthritis Drug Sale, by Route of Administration, End-users, Distribution Channel, Drug Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Rheumatoid Arthritis Drug (Value)
      • 7.2.1. Global Rheumatoid Arthritis Drug by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Parenteral
      • 7.2.2. Global Rheumatoid Arthritis Drug by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Rheumatoid Arthritis Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Rheumatoid Arthritis Drug by: Drug Class (Value)
        • 7.2.4.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • 7.2.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.2.4.3. Corticosteroids
        • 7.2.4.4. Uric Acid Drugs
        • 7.2.4.5. Others
      • 7.2.5. Global Rheumatoid Arthritis Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Rheumatoid Arthritis Drug (Volume)
      • 7.3.1. Global Rheumatoid Arthritis Drug by: Route of Administration (Volume)
        • 7.3.1.1. Oral
        • 7.3.1.2. Parenteral
      • 7.3.2. Global Rheumatoid Arthritis Drug by: End-users (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Ambulatory Surgical Centres
        • 7.3.2.4. Others
      • 7.3.3. Global Rheumatoid Arthritis Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
        • 7.3.3.4. Others
      • 7.3.4. Global Rheumatoid Arthritis Drug by: Drug Class (Volume)
        • 7.3.4.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • 7.3.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.3.4.3. Corticosteroids
        • 7.3.4.4. Uric Acid Drugs
        • 7.3.4.5. Others
      • 7.3.5. Global Rheumatoid Arthritis Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Rheumatoid Arthritis Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rheumatoid Arthritis Drug: by Route of Administration(USD Million)
  • Table 2. Rheumatoid Arthritis Drug Oral , by Region USD Million (2015-2020)
  • Table 3. Rheumatoid Arthritis Drug Parenteral , by Region USD Million (2015-2020)
  • Table 4. Rheumatoid Arthritis Drug: by End-users(USD Million)
  • Table 5. Rheumatoid Arthritis Drug Hospitals , by Region USD Million (2015-2020)
  • Table 6. Rheumatoid Arthritis Drug Clinics , by Region USD Million (2015-2020)
  • Table 7. Rheumatoid Arthritis Drug Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 8. Rheumatoid Arthritis Drug Others , by Region USD Million (2015-2020)
  • Table 9. Rheumatoid Arthritis Drug: by Distribution Channel(USD Million)
  • Table 10. Rheumatoid Arthritis Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Rheumatoid Arthritis Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Rheumatoid Arthritis Drug Online , by Region USD Million (2015-2020)
  • Table 13. Rheumatoid Arthritis Drug Others , by Region USD Million (2015-2020)
  • Table 14. Rheumatoid Arthritis Drug: by Drug Class(USD Million)
  • Table 15. Rheumatoid Arthritis Drug Disease-modifying Anti-rheumatic Drugs (DMARDs) , by Region USD Million (2015-2020)
  • Table 16. Rheumatoid Arthritis Drug Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2015-2020)
  • Table 17. Rheumatoid Arthritis Drug Corticosteroids , by Region USD Million (2015-2020)
  • Table 18. Rheumatoid Arthritis Drug Uric Acid Drugs , by Region USD Million (2015-2020)
  • Table 19. Rheumatoid Arthritis Drug Others , by Region USD Million (2015-2020)
  • Table 20. South America Rheumatoid Arthritis Drug, by Country USD Million (2015-2020)
  • Table 21. South America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 22. South America Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 23. South America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 24. South America Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 25. Brazil Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 26. Brazil Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 27. Brazil Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 28. Brazil Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 29. Argentina Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 30. Argentina Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 31. Argentina Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 32. Argentina Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 33. Rest of South America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 34. Rest of South America Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 35. Rest of South America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 36. Rest of South America Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 37. Asia Pacific Rheumatoid Arthritis Drug, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 39. Asia Pacific Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 40. Asia Pacific Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 41. Asia Pacific Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 42. China Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 43. China Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 44. China Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 45. China Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 46. Japan Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 47. Japan Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 48. Japan Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 49. Japan Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 50. India Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 51. India Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 52. India Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 53. India Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 54. South Korea Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 55. South Korea Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 56. South Korea Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 57. South Korea Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 58. Taiwan Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 59. Taiwan Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 60. Taiwan Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 61. Taiwan Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 62. Australia Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 63. Australia Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 64. Australia Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 65. Australia Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 70. Europe Rheumatoid Arthritis Drug, by Country USD Million (2015-2020)
  • Table 71. Europe Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 72. Europe Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 73. Europe Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 74. Europe Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 75. Germany Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 76. Germany Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 77. Germany Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 78. Germany Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 79. France Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 80. France Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 81. France Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 82. France Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 83. Italy Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 84. Italy Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 85. Italy Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 86. Italy Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 87. United Kingdom Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 88. United Kingdom Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 89. United Kingdom Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 90. United Kingdom Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 91. Netherlands Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 92. Netherlands Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 93. Netherlands Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 94. Netherlands Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 95. Rest of Europe Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 96. Rest of Europe Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 97. Rest of Europe Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 98. Rest of Europe Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 99. MEA Rheumatoid Arthritis Drug, by Country USD Million (2015-2020)
  • Table 100. MEA Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 101. MEA Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 102. MEA Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 103. MEA Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 104. Middle East Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 105. Middle East Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 106. Middle East Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 107. Middle East Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 108. Africa Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 109. Africa Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 110. Africa Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 111. Africa Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 112. North America Rheumatoid Arthritis Drug, by Country USD Million (2015-2020)
  • Table 113. North America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 114. North America Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 115. North America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 116. North America Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 117. United States Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 118. United States Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 119. United States Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 120. United States Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 121. Canada Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 122. Canada Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 123. Canada Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 124. Canada Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 125. Mexico Rheumatoid Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 126. Mexico Rheumatoid Arthritis Drug, by End-users USD Million (2015-2020)
  • Table 127. Mexico Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2015-2020)
  • Table 128. Mexico Rheumatoid Arthritis Drug, by Drug Class USD Million (2015-2020)
  • Table 129. Rheumatoid Arthritis Drug Sales: by Route of Administration(K Units)
  • Table 130. Rheumatoid Arthritis Drug Sales Oral , by Region K Units (2015-2020)
  • Table 131. Rheumatoid Arthritis Drug Sales Parenteral , by Region K Units (2015-2020)
  • Table 132. Rheumatoid Arthritis Drug Sales: by End-users(K Units)
  • Table 133. Rheumatoid Arthritis Drug Sales Hospitals , by Region K Units (2015-2020)
  • Table 134. Rheumatoid Arthritis Drug Sales Clinics , by Region K Units (2015-2020)
  • Table 135. Rheumatoid Arthritis Drug Sales Ambulatory Surgical Centres , by Region K Units (2015-2020)
  • Table 136. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2015-2020)
  • Table 137. Rheumatoid Arthritis Drug Sales: by Distribution Channel(K Units)
  • Table 138. Rheumatoid Arthritis Drug Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 139. Rheumatoid Arthritis Drug Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 140. Rheumatoid Arthritis Drug Sales Online , by Region K Units (2015-2020)
  • Table 141. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2015-2020)
  • Table 142. Rheumatoid Arthritis Drug Sales: by Drug Class(K Units)
  • Table 143. Rheumatoid Arthritis Drug Sales Disease-modifying Anti-rheumatic Drugs (DMARDs) , by Region K Units (2015-2020)
  • Table 144. Rheumatoid Arthritis Drug Sales Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region K Units (2015-2020)
  • Table 145. Rheumatoid Arthritis Drug Sales Corticosteroids , by Region K Units (2015-2020)
  • Table 146. Rheumatoid Arthritis Drug Sales Uric Acid Drugs , by Region K Units (2015-2020)
  • Table 147. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2015-2020)
  • Table 148. South America Rheumatoid Arthritis Drug Sales, by Country K Units (2015-2020)
  • Table 149. South America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 150. South America Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 151. South America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 152. South America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 153. Brazil Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 154. Brazil Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 155. Brazil Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 156. Brazil Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 157. Argentina Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 158. Argentina Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 159. Argentina Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 160. Argentina Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 161. Rest of South America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 162. Rest of South America Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 163. Rest of South America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. Rest of South America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 165. Asia Pacific Rheumatoid Arthritis Drug Sales, by Country K Units (2015-2020)
  • Table 166. Asia Pacific Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 167. Asia Pacific Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 168. Asia Pacific Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 169. Asia Pacific Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 170. China Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 171. China Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 172. China Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. China Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 174. Japan Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 175. Japan Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 176. Japan Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. Japan Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 178. India Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 179. India Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 180. India Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 181. India Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 182. South Korea Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 183. South Korea Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 184. South Korea Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 185. South Korea Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 186. Taiwan Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 187. Taiwan Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 188. Taiwan Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Taiwan Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 190. Australia Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 191. Australia Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 192. Australia Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Australia Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 194. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 195. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 196. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 197. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 198. Europe Rheumatoid Arthritis Drug Sales, by Country K Units (2015-2020)
  • Table 199. Europe Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 200. Europe Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 201. Europe Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 202. Europe Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 203. Germany Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 204. Germany Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 205. Germany Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. Germany Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 207. France Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 208. France Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 209. France Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 210. France Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 211. Italy Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 212. Italy Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 213. Italy Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 214. Italy Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 215. United Kingdom Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 216. United Kingdom Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 217. United Kingdom Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 218. United Kingdom Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 219. Netherlands Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 220. Netherlands Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 221. Netherlands Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 222. Netherlands Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 223. Rest of Europe Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 224. Rest of Europe Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 225. Rest of Europe Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 226. Rest of Europe Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 227. MEA Rheumatoid Arthritis Drug Sales, by Country K Units (2015-2020)
  • Table 228. MEA Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 229. MEA Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 230. MEA Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 231. MEA Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 232. Middle East Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 233. Middle East Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 234. Middle East Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. Middle East Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 236. Africa Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 237. Africa Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 238. Africa Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 239. Africa Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 240. North America Rheumatoid Arthritis Drug Sales, by Country K Units (2015-2020)
  • Table 241. North America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 242. North America Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 243. North America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 244. North America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 245. United States Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 246. United States Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 247. United States Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 248. United States Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 249. Canada Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 250. Canada Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 251. Canada Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 252. Canada Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 253. Mexico Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 254. Mexico Rheumatoid Arthritis Drug Sales, by End-users K Units (2015-2020)
  • Table 255. Mexico Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 256. Mexico Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2015-2020)
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Rheumatoid Arthritis Drug: by Route of Administration(USD Million)
  • Table 269. Rheumatoid Arthritis Drug Oral , by Region USD Million (2021-2026)
  • Table 270. Rheumatoid Arthritis Drug Parenteral , by Region USD Million (2021-2026)
  • Table 271. Rheumatoid Arthritis Drug: by End-users(USD Million)
  • Table 272. Rheumatoid Arthritis Drug Hospitals , by Region USD Million (2021-2026)
  • Table 273. Rheumatoid Arthritis Drug Clinics , by Region USD Million (2021-2026)
  • Table 274. Rheumatoid Arthritis Drug Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 275. Rheumatoid Arthritis Drug Others , by Region USD Million (2021-2026)
  • Table 276. Rheumatoid Arthritis Drug: by Distribution Channel(USD Million)
  • Table 277. Rheumatoid Arthritis Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 278. Rheumatoid Arthritis Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 279. Rheumatoid Arthritis Drug Online , by Region USD Million (2021-2026)
  • Table 280. Rheumatoid Arthritis Drug Others , by Region USD Million (2021-2026)
  • Table 281. Rheumatoid Arthritis Drug: by Drug Class(USD Million)
  • Table 282. Rheumatoid Arthritis Drug Disease-modifying Anti-rheumatic Drugs (DMARDs) , by Region USD Million (2021-2026)
  • Table 283. Rheumatoid Arthritis Drug Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2021-2026)
  • Table 284. Rheumatoid Arthritis Drug Corticosteroids , by Region USD Million (2021-2026)
  • Table 285. Rheumatoid Arthritis Drug Uric Acid Drugs , by Region USD Million (2021-2026)
  • Table 286. Rheumatoid Arthritis Drug Others , by Region USD Million (2021-2026)
  • Table 287. South America Rheumatoid Arthritis Drug, by Country USD Million (2021-2026)
  • Table 288. South America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 289. South America Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 290. South America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 291. South America Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 292. Brazil Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 293. Brazil Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 294. Brazil Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 295. Brazil Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 296. Argentina Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 297. Argentina Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 298. Argentina Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 299. Argentina Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 300. Rest of South America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 301. Rest of South America Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 302. Rest of South America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 303. Rest of South America Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 304. Asia Pacific Rheumatoid Arthritis Drug, by Country USD Million (2021-2026)
  • Table 305. Asia Pacific Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 306. Asia Pacific Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 307. Asia Pacific Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 308. Asia Pacific Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 309. China Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 310. China Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 311. China Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 312. China Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 313. Japan Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 314. Japan Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 315. Japan Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 316. Japan Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 317. India Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 318. India Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 319. India Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 320. India Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 321. South Korea Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 322. South Korea Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 323. South Korea Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 324. South Korea Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 325. Taiwan Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 326. Taiwan Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 327. Taiwan Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 328. Taiwan Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 329. Australia Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 330. Australia Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 331. Australia Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 332. Australia Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 333. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 334. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 335. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 336. Rest of Asia-Pacific Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 337. Europe Rheumatoid Arthritis Drug, by Country USD Million (2021-2026)
  • Table 338. Europe Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 339. Europe Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 340. Europe Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 341. Europe Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 342. Germany Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 343. Germany Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 344. Germany Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 345. Germany Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 346. France Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 347. France Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 348. France Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 349. France Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 350. Italy Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 351. Italy Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 352. Italy Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 353. Italy Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 354. United Kingdom Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 355. United Kingdom Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 356. United Kingdom Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 357. United Kingdom Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 358. Netherlands Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 359. Netherlands Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 360. Netherlands Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 361. Netherlands Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 362. Rest of Europe Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 363. Rest of Europe Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 364. Rest of Europe Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 365. Rest of Europe Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 366. MEA Rheumatoid Arthritis Drug, by Country USD Million (2021-2026)
  • Table 367. MEA Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 368. MEA Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 369. MEA Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 370. MEA Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 371. Middle East Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 372. Middle East Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 373. Middle East Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 374. Middle East Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 375. Africa Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 376. Africa Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 377. Africa Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 378. Africa Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 379. North America Rheumatoid Arthritis Drug, by Country USD Million (2021-2026)
  • Table 380. North America Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 381. North America Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 382. North America Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 383. North America Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 384. United States Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 385. United States Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 386. United States Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 387. United States Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 388. Canada Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 389. Canada Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 390. Canada Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 391. Canada Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 392. Mexico Rheumatoid Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 393. Mexico Rheumatoid Arthritis Drug, by End-users USD Million (2021-2026)
  • Table 394. Mexico Rheumatoid Arthritis Drug, by Distribution Channel USD Million (2021-2026)
  • Table 395. Mexico Rheumatoid Arthritis Drug, by Drug Class USD Million (2021-2026)
  • Table 396. Rheumatoid Arthritis Drug Sales: by Route of Administration(K Units)
  • Table 397. Rheumatoid Arthritis Drug Sales Oral , by Region K Units (2021-2026)
  • Table 398. Rheumatoid Arthritis Drug Sales Parenteral , by Region K Units (2021-2026)
  • Table 399. Rheumatoid Arthritis Drug Sales: by End-users(K Units)
  • Table 400. Rheumatoid Arthritis Drug Sales Hospitals , by Region K Units (2021-2026)
  • Table 401. Rheumatoid Arthritis Drug Sales Clinics , by Region K Units (2021-2026)
  • Table 402. Rheumatoid Arthritis Drug Sales Ambulatory Surgical Centres , by Region K Units (2021-2026)
  • Table 403. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2021-2026)
  • Table 404. Rheumatoid Arthritis Drug Sales: by Distribution Channel(K Units)
  • Table 405. Rheumatoid Arthritis Drug Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 406. Rheumatoid Arthritis Drug Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 407. Rheumatoid Arthritis Drug Sales Online , by Region K Units (2021-2026)
  • Table 408. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2021-2026)
  • Table 409. Rheumatoid Arthritis Drug Sales: by Drug Class(K Units)
  • Table 410. Rheumatoid Arthritis Drug Sales Disease-modifying Anti-rheumatic Drugs (DMARDs) , by Region K Units (2021-2026)
  • Table 411. Rheumatoid Arthritis Drug Sales Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region K Units (2021-2026)
  • Table 412. Rheumatoid Arthritis Drug Sales Corticosteroids , by Region K Units (2021-2026)
  • Table 413. Rheumatoid Arthritis Drug Sales Uric Acid Drugs , by Region K Units (2021-2026)
  • Table 414. Rheumatoid Arthritis Drug Sales Others , by Region K Units (2021-2026)
  • Table 415. South America Rheumatoid Arthritis Drug Sales, by Country K Units (2021-2026)
  • Table 416. South America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 417. South America Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 418. South America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 419. South America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 420. Brazil Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 421. Brazil Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 422. Brazil Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 423. Brazil Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 424. Argentina Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 425. Argentina Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 426. Argentina Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 427. Argentina Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 428. Rest of South America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 429. Rest of South America Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 430. Rest of South America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 431. Rest of South America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 432. Asia Pacific Rheumatoid Arthritis Drug Sales, by Country K Units (2021-2026)
  • Table 433. Asia Pacific Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 434. Asia Pacific Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 435. Asia Pacific Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 436. Asia Pacific Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 437. China Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 438. China Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 439. China Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 440. China Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 441. Japan Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 442. Japan Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 443. Japan Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 444. Japan Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 445. India Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 446. India Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 447. India Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 448. India Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 449. South Korea Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 450. South Korea Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 451. South Korea Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 452. South Korea Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 453. Taiwan Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 454. Taiwan Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 455. Taiwan Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 456. Taiwan Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 457. Australia Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 458. Australia Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 459. Australia Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 460. Australia Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 461. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 462. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 463. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 464. Rest of Asia-Pacific Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 465. Europe Rheumatoid Arthritis Drug Sales, by Country K Units (2021-2026)
  • Table 466. Europe Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 467. Europe Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 468. Europe Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 469. Europe Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 470. Germany Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 471. Germany Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 472. Germany Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 473. Germany Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 474. France Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 475. France Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 476. France Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 477. France Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 478. Italy Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 479. Italy Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 480. Italy Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 481. Italy Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 482. United Kingdom Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 483. United Kingdom Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 484. United Kingdom Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 485. United Kingdom Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 486. Netherlands Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 487. Netherlands Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 488. Netherlands Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 489. Netherlands Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 490. Rest of Europe Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 491. Rest of Europe Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 492. Rest of Europe Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 493. Rest of Europe Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 494. MEA Rheumatoid Arthritis Drug Sales, by Country K Units (2021-2026)
  • Table 495. MEA Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 496. MEA Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 497. MEA Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. MEA Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 499. Middle East Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 500. Middle East Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 501. Middle East Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 502. Middle East Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 503. Africa Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 504. Africa Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 505. Africa Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 506. Africa Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 507. North America Rheumatoid Arthritis Drug Sales, by Country K Units (2021-2026)
  • Table 508. North America Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 509. North America Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 510. North America Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 511. North America Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 512. United States Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 513. United States Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 514. United States Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 515. United States Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 516. Canada Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 517. Canada Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 518. Canada Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 519. Canada Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 520. Mexico Rheumatoid Arthritis Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 521. Mexico Rheumatoid Arthritis Drug Sales, by End-users K Units (2021-2026)
  • Table 522. Mexico Rheumatoid Arthritis Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 523. Mexico Rheumatoid Arthritis Drug Sales, by Drug Class K Units (2021-2026)
  • Table 524. Research Programs/Design for This Report
  • Table 525. Key Data Information from Secondary Sources
  • Table 526. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rheumatoid Arthritis Drug: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Rheumatoid Arthritis Drug: by End-users USD Million (2015-2020)
  • Figure 6. Global Rheumatoid Arthritis Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Rheumatoid Arthritis Drug: by Drug Class USD Million (2015-2020)
  • Figure 8. South America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 9. Asia Pacific Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 10. Europe Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 11. MEA Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 12. North America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 13. Global Rheumatoid Arthritis Drug: by Route of Administration K Units (2015-2020)
  • Figure 14. Global Rheumatoid Arthritis Drug: by End-users K Units (2015-2020)
  • Figure 15. Global Rheumatoid Arthritis Drug: by Distribution Channel K Units (2015-2020)
  • Figure 16. Global Rheumatoid Arthritis Drug: by Drug Class K Units (2015-2020)
  • Figure 17. South America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 18. Asia Pacific Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 19. Europe Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 20. MEA Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 21. North America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 22. Global Rheumatoid Arthritis Drug share by Players 2020 (%)
  • Figure 23. Global Rheumatoid Arthritis Drug share by Players (Top 3) 2020(%)
  • Figure 24. Global Rheumatoid Arthritis Drug share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 28. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 29. UCB S.A. (Belgium) Revenue: by Geography 2020
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 32. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 38. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 40. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 42. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 43. Pfizer (United States) Revenue: by Geography 2020
  • Figure 44. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 45. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 46. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 47. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 48. Global Rheumatoid Arthritis Drug: by Route of Administration USD Million (2021-2026)
  • Figure 49. Global Rheumatoid Arthritis Drug: by End-users USD Million (2021-2026)
  • Figure 50. Global Rheumatoid Arthritis Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 51. Global Rheumatoid Arthritis Drug: by Drug Class USD Million (2021-2026)
  • Figure 52. South America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 53. Asia Pacific Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 54. Europe Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 55. MEA Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 56. North America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 57. Global Rheumatoid Arthritis Drug: by Route of Administration K Units (2021-2026)
  • Figure 58. Global Rheumatoid Arthritis Drug: by End-users K Units (2021-2026)
  • Figure 59. Global Rheumatoid Arthritis Drug: by Distribution Channel K Units (2021-2026)
  • Figure 60. Global Rheumatoid Arthritis Drug: by Drug Class K Units (2021-2026)
  • Figure 61. South America Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 62. Asia Pacific Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 63. Europe Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 64. MEA Rheumatoid Arthritis Drug Share (%), by Country
  • Figure 65. North America Rheumatoid Arthritis Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Amgen Inc. (United States)
  • UCB S.A. (Belgium)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • AbbVie Inc. (United States)
  • Boehringer Ingelheim (Germany)
  • Novartis International AG (Switzerland)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • Pfizer (United States)
  • Bristol-Myers Squibb Company (United States)
  • Johnson & Johnson (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation